Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhida Liu

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Nature Immunology|April 2, 2020
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signalingChuanhui Han, Zhida Liu, Yunjia Zhang, et al.
Journal for Immunotherapy of Cancer|May 27, 2022
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapyXiaoyi Jiang, Jian Wang, Xichen Zheng, et al.
Physical Review Letters|February 10, 2025
Valley-Mediated Singlet- and Triplet-Polaron Interactions and Quantum Dynamics in a Doped WSe_{2} MonolayerYue Ni, Di Huang, Danfu Liang, et al.
Science Immunology|August 11, 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunityZhida Liu, Chuanhui Han, Chunbo Dong, et al.
Nature Communications|August 30, 2019
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8<sup>+</sup> T-cell response and effective tumor controlZhichen Sun, Zhenhua Ren, Kaiting Yang, et al.
Nature Communications|April 3, 2020
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8<sup>+</sup> T-cell response and effective tumor controlZhichen Sun, Zhenhua Ren, Kaiting Yang, et al.
Nature Communications|September 6, 2022
Lactate increases stemness of CD8 + T cells to augment anti-tumor immunityQiang Feng, Zhida Liu, Xuexin Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2022
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor EffectXuejun Wen, Changrong Shi, Xinying Zeng, et al.
Science Advances|May 9, 2025
Moiré ferroelectricity modulates light emission from a semiconductor monolayerDong Seob Kim, Chengxin Xiao, Roy C Dominguez, et al.
Materials Today. Bio|December 16, 2025
A tripartite therapeutic agent reprograms the myocardial infarction microenvironmentKaiyi Zhu, Xiaozhe Wang, Qian Yang, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Nature Immunology|April 2, 2020
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signalingChuanhui Han, Zhida Liu, Yunjia Zhang, et al.
Journal for Immunotherapy of Cancer|May 27, 2022
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapyXiaoyi Jiang, Jian Wang, Xichen Zheng, et al.
Physical Review Letters|February 10, 2025
Valley-Mediated Singlet- and Triplet-Polaron Interactions and Quantum Dynamics in a Doped WSe_{2} MonolayerYue Ni, Di Huang, Danfu Liang, et al.
Science Immunology|August 11, 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunityZhida Liu, Chuanhui Han, Chunbo Dong, et al.
Nature Communications|August 30, 2019
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8<sup>+</sup> T-cell response and effective tumor controlZhichen Sun, Zhenhua Ren, Kaiting Yang, et al.
Nature Communications|April 3, 2020
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8<sup>+</sup> T-cell response and effective tumor controlZhichen Sun, Zhenhua Ren, Kaiting Yang, et al.
Nature Communications|September 6, 2022
Lactate increases stemness of CD8 + T cells to augment anti-tumor immunityQiang Feng, Zhida Liu, Xuexin Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2022
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor EffectXuejun Wen, Changrong Shi, Xinying Zeng, et al.
Science Advances|May 9, 2025
Moiré ferroelectricity modulates light emission from a semiconductor monolayerDong Seob Kim, Chengxin Xiao, Roy C Dominguez, et al.
Materials Today. Bio|December 16, 2025
A tripartite therapeutic agent reprograms the myocardial infarction microenvironmentKaiyi Zhu, Xiaozhe Wang, Qian Yang, et al.
Pageof 7